Adaptive Biotechnologies faces losses but shows strong sales value and liquidity ahead of Q1 2026 earnings.

Adaptive Biotechnologies Corporation, focusing on immune system research, reports a challenging financial position with negative profitability and operating cash flow. Despite losses reflected in a negative P/E ratio of -38.02 and earnings yield of -2.63%, the market values its sales highly with a price-to-sales ratio of 8.21. Insider selling by the COO occurred just before the Q1 2026 earnings announcement scheduled for May 5, 2026. The company maintains strong short-term liquidity with a current ratio of 3.34, indicating financial stability despite using debt to finance assets. Investors will closely watch the upcoming earnings report for insights into the company's future performance.